Provided herein are programmable condensate protein systems and nucleic acid constructs encoding the same. The protein system enables modular targeting of proteins of interest. Protein-peptide interaction domains (PPIDs) are incorporated to functionalize engineered condensates with the attributes of the recruited protein, resulting in a modular system that allows for diverse facile and reprogrammable applications, including in enzyme clustering of metabolic pathways. Colocalizing specific metabolic enzymes in these condensates results in functionalized organelles with which can be used to manipulate the output of engineered metabolic pathways for the production of a pharmaceutical precursor.

The present invention pertains to a method for identifying and/or characterizing a compound suitable for the prevention and/or treatment of a disease. The invention is based on the finding that the glycolytic enzyme Enolase 1 (ENO1) binds RNA, and its enzymatic activity is thereby regulated. The invention is further based on the finding that riboregulation of ENO1 affects cell differentiation, which plays a pivotal role in cancer. Accordingly, the invention provides a screening method for novel therapeutic compounds based on the binding of RNA to ENO1. Compounds screened according to the present invention can affect the binding of RNA to ENO1, which harbors the therapeutic potential for the treatment of diseases, in particular proliferative diseases, such as cancer. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.

The present invention relates to epitopes containing homocitrulline (Hcit) that can be used as targets for cancer immunotherapy. The homocitrullinated T cell epitope has (i) a predicted binding score to MHC class II or class I of <30 using the online IEDB prediction program (http://www.iedb.org/) and (ii) at least 5 consecutive amino acids that form a spiral conformational structure. These modified peptides can be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies.

The present invention relates to modified citrullinated enolase peptides that can be used as targets for cancer immunotherapy. These peptides can be used as vaccines or as targets for monoclonal antibody (mAb) therapy. Such vaccines cur mAbs may be used in the treatment of cancer.

The present invention provides a cell which expresses a chimeric antigen receptor (CAR) or engineered T-cell receptor (TCR) and secretes an agent which blocks or reduces the activity of an ectoenzyme. The cells may be used in adoptive immunotherapy approaches for the treatment of diseases such as cancer.

Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of brain injuries, especially mild traumatic brain injury (mTBI) or concussion, are based upon detection of changes in levels of certain protein biomarkers in a subject undergoing testing, or upon detection of changes in levels of certain protein biomarkers in conjunction with neuroimaging analyses to detect changes in vascular or blood brain barrier (BBB) permeability in the brain, or to detect damage to fiber tracts in the brain, in which changes in biomarker levels correlate with detection of changes in BBB permeability or in brain fiber tract or white matter damage in a subject with brain injury such as mTBI or concussion.

The invention provides compositions comprising Eno1 and a muscle targeting peptide, e.g, as a fusion protein, for delivery of Eno1 to a muscle. The Eno1 may contain one or more added cysteine residues which are covalently attached to a biocompatible polymer (e.g. polyethylene glycol). Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject.

The invention provides anti-CaENO1 antibodies and humanized antibodies as effective diagnostic agent or therapeutic treatment against infections caused by Candida spp. (preferably Candida. albicans, Candida tropicalis), fluconazole resistance Candida spp., Streptococcus, or Staphylococcus.

Methods and materials related to producing glyceric acid and downstream products are disclosed. Specifically, isolated nucleic acids, polypeptides, host cells, methods and materials for producing glycolic acid by direct fermentation from sugars are disclosed.

The present invention relates to a recombinant microorganism having enhanced ability to produce recombinant silk protein and a method of producing high-molecular-weight recombinant silk protein using the same, and more specifically, to a recombinant microorganism having an enhanced ability to produce spider silk protein, obtained by introducing a sequence encoding a synthetic sRNA that inhibits expression of eno gene into a microorganism having ability to produce recombinant silk protein. The recombinant silk protein derived from the recombinant strain according to the invention has a high molecular weight similar to that of dragline silk protein produced by spiders, and may be mass-produced, and thus it has properties similar to or better than those of natural silk protein when manufactured into fibers. Accordingly, the recombinant silk protein may be advantageously used in various industrial fields such as bioengineering and/or pharmaceutical fields where spider silk fibers are expected to be applied.